Introduction
Although most fractures in humans show normal bone healing, approximately 5% per year do not heal and are classified as delayed or nonunions. Difficult bone loss problems may be associated with trauma, revision total joint arthroplasty, pseudoarthrosis of the spine and tumor resection. Autologous bone graft is considered to be the gold standard bone graft material, but there is only a limited quantity of bone available to harvest. Moreover, harvesting of autologous bone grafts has significant morbidity, including persistent donor site pain, local infection and paresthesias. [1] [2] [3] These limitations have prompted an increased interest in identifying bone graft substitutes.
The clinical potential of growth factors to enhance fracture repair has been recognized for decades but sustained, therapeutic concentrations of the appropriate growth factors at the bone repair site are necessary to produce an adequate osteoinductive response. When compared to other known growth factors, the bone morphogenetic proteins (BMPs) -2 and -7 (also known as osteogenic protein-1(OP-1)) have the most robust osteoinductive activity as noted in both preclinical animal studies and in human trials. 42 However, large doses of BMPs have been required to induce adequate bone formation in humans. 4 The side effects of such large protein doses are unknown, but it is clear that protein delivery needs to be optimized. Furthermore, there are concerns that a single dose of recombinant protein may not be sufficient to yield an adequate osteoinductive response, particularly in cases where there is compromised bone stock and vascularity. 5, 6 Regional gene therapy is another approach to deliver proteins to a specific anatomic site.
Evans and Robbins 3 have given a detailed description of the basic concepts of gene therapy and its application to orthopedic problems at large. Different methods of gene transfer are currently being investigated for the purpose of enhancing bone repair. The results of various preclinical studies have demonstrated the clinical potential of gene therapy and suggest that, in the future, gene therapy may be one of the tools available to orthopedic surgeons to treat difficult bone loss problems. However, since this is an application of gene therapy for the treatment of nonlethal conditions, patient safety is of paramount importance. Even a small increase in either morbidity or mortality associated with any gene therapy treatment regimen will not be acceptable to either orthopedic surgeons or the public.
Regional gene therapy
Regional gene therapy can be employed via either an in vivo or an ex vivo approach. In an in vivo technique, the vector is delivered directly to the anatomic site. In an ex vivo approach, specific cells are harvested from the patient, and then transduced outside the body; the transduced cells are then reimplanted into a specific anatomic site (Figure 1 ). The advantage of the in vivo approach is that it involves only one step and if an offthe-shelf technology could be developed, it would be quite popular with surgeons. The disadvantages of this technique are that it is more difficult to transduce cells in vivo, and one cannot select the target cells that will be transduced. Theoretically, all cells at the bone repair site are candidates to be transduced. 36, 38 The advantage of the ex vivo technique is that there is an increased transduction efficiency when performed in an in vitro setting and a specific cellular delivery vehicle can be selected. The disadvantage of this strategy is that this approach is more labor intensive, and therefore may not be cost-effective. One of the more challenging issues related to the development of gene therapy as a treatment modality is that long-term protein production is usually necessary. In contrast, regional gene therapy to enhance bone repair only requires protein expression until the bone is healed. Therefore, there is more flexibility with respect to the use of vectors for treatment of these problems. Viral vectors and nonviral vectors are presently being investigated as potential gene delivery vehicles to enhance bone repair. The selection of an appropriated viral vector for a bone repair strategy will be determined by the duration of the protein expression that is necessary, and whether or not the vector can be used via an in vivo or ex vivo approach.
A variety of viral vectors are being studied at this time as potential gene delivery vehicles. [45] [46] [47] [48] [49] A detailed discussion of the advantages and disadvantages of the use of adenoviral, adeno-associated, retroviral and lentiviral vectors is beyond the scope of this review. At the present time, recombinant adenoviral vectors have received the most attention because these vectors can be produced in high titers, and can easily infect both dividing and nondividing cells. The expression of the transferred gene is often very high initially, but tends to decrease rapidly with time. This transient protein production is a problem when trying to treat diseases associated with single gene defects such as cystic fibrosis, but it is not a limitation when trying to treat many bone repair problems. The loss of gene expression occurs because the transferred DNA remains episomal, and there is an immunogenic response to viral proteins that are produced in addition to the gene of interest. After transduction, viral proteins are presented on the cell surface, which attracts immunocompetent cells including cytotoxic T-lymphocytes. The immune response to these adenoviral proteins is a major obstacle to the adaptation of adenoviral gene therapy to treat nonlethal musculoskeletal problems in humans. Adenoviral vectors are known to transduce a variety of cell types involved in bone healing, 7 such as osteoblasts, 8 myoblasts and various types of bone marrow cells, including mesenchymal stem cells. 9, 10 Nonviral vectors are easier to produce than their viral counterparts and they often have greater chemical stability. These vectors may include liposomes, gene gun or naked DNA. These nonviral vectors also deliver the DNA in an episomal manner. The use of nonviral DNA delivery systems for gene therapy offers a number of attractive features compared to viral systems, including ease of manipulation, safety and stability upon storage. In addition, since these vectors do not use strongly antigenic materials, they should not evoke a strong immunogenic response and repeated administration should be possible. The major disadvantage of these techniques is a low in vivo transfection efficiency, which may limit their overall efficacy.
In vivo gene transfer
There is significant interest in developing an in vivo gene transfer approach because it would be technically simple to use in the operating room. Both direct adenoviral gene transfer and a gene-activated matrix (GAM) have been used in preclinical animal studies.
Musgrave et al 11 induced ectopic bone formation using a BMP-2-containing adenovirus injected into the thigh muscles of mice. Bone formation was noted, but the amount of bone formed was significantly less in immune-competent compared to immune-compromised animals. Baltzer et al directly injected an adenovirus containing the cDNA for BMP-2 (Ad.BMP-2) into a critical-sized defect in a rabbit femur ( Figure 2 ). Radiologic, histologic and biomechanical analysis demonstrated that defects treated with the adenovirus healed the osseous lesions, whereas the control defects were predominantly fibrotic, sparsely ossified and unstable. 7, 37 Direct injection of a BMP-2-containing adenovirus has also been used to accelerate bone healing in critical-sized mandibular defects in rodents. 12 First-generation adenoviral vectors induce an immune response, which decreases gene expression over time and limits the effectiveness of repeat dosing. [13] [14] [15] [16] The However, the successful stimulation of bone repair after in vivo application of Ad.BMP-2 into femoral defects of immune-competent animals demonstrates the importance of the location of the anatomic site being treated. 7 Furthermore, the successful redosing of an adenoviral vector after strict local application to the iliac crest of sheep, including increase of marker gene expression following the second dose of virus, further underscores the importance of the location of administration of the adenovirus. 19 Transient immunosuppression could address the problems of the immune response associated with direct adenoviral injection. Okubo et al evaluated osteoinduction in the calf muscle of rats after treatment with 125 mg/kg cyclophosphamide the day before injection of an Ad.BMP-2 vector. Ectopic bone formation occurred when the animals were transiently immunosuppressed in this manner. 7, 20, 21 The results indicate that transient immunosuppression may be used to promote bone repair when using adenoviral gene transfer strategy. However, systemic administration of an immunosuppressive agent may not be an acceptable strategy to enhance bone repair in otherwise healthy patients, and could have deleterious effects on the bone itself. The development of helper-dependent adenoviral vectors that have most viral coding regions deleted may contribute to an eventual solution for this immunogenic issue.
To avoid potential problems associated with viral vectors, nonviral delivery methods are being explored. Plasmid DNA encoding products such as parathyroid hormone (PTH) 1-34 or BMP-4 were incorporated into a collagen sponge to create a GAM. The GAM is implanted directly into the bone defect, where cells in the region can then pick up this DNA and become local bioreactors for the synthesis of the encoded OPs. This strategy was successfully used to heal 5-mm defects in rats. A combination of cDNAs encoding PTH 1-34 and BMP-4 induced better bone repair than the GAM with either BMP-4 or PTH 1-34 cDNAs alone. 22, 39 In a subsequent study, Bonadio et al implanted a GAM containing the PTH 1-34 cDNA in a critical-sized tibial defect in a canine model. 23 At 6 weeks in vivo protein production was noted, but insufficient bone was produced to heal the critical-sized defect. The results of this study suggest that either the local transfection efficiency of the GAM is low or perhaps PTH has a limited osteoinductive potential in this setting. The concept of using GAM technology to deliver cDNAs encoding OPs is quite attractive. Further studies are necessary to select the cDNA with the most osteoinductive potential to be implanted into this matrix, the optimal matrix material Figure 2 Treatment of critical-sized femoral defects with in vivo regional gene therapy with adenoviral gene transfer. Critical-sized defects (1.3 cm) were created in the femurs of rabbits. Ad.BMP-2 or, as a control, Ad.luciferase was injected into the defect site. After 12 weeks, defects receiving Ad.BMP-2 had achieved union, whereas those receiving Ad.luciferase had not.
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and a complete evaluation of the host immune responses to this form of nonviral gene delivery.
Ex vivo gene transfer
The advantage of an ex vivo gene transfer approach is that the surgeon can select specific cells (ie bone marrow cells or stem cells) as the cellular delivery vehicle for specific clinical problems. The ex vivo technique may also be safer than an in vivo strategy when working with an adenovirus because no viral particles or DNA complexes are injected directly into the body. In addition, ex vivo strategies have a high efficiency of cell transduction. The disadvantage of this strategy is that an extra harvesting step is required and this can increase the time and cost of the process. However, it is possible to harvest cells from the patient, have a very short period of infection and reimplant the transduced cells at the appropriate anatomic site. 24, 41 This strategy would make it much more user-friendly for surgeons than to harvest cells, expand them in tissue culture and reimplant them in a patient.
The cells that have received the most interest as a cellular delivery vehicle are mesenchymal stem cells, muscle-derived stem cells, adipose-derived stem cells, buffy coat cells from bone marrow or blood and skin fibroblasts. A potential advantage of using bone marrow or stem cells is that both autocrine and paracrine responses can be elicited to enhance bone repair. These cells have the ability to not only secrete an osteoinductive protein such as BMP-2 but also respond to it. Bone marrow cells are obvious candidates for ex vivo gene transfer to enhance bone healing because they are osteogenic. In addition, bone marrow cell harvest is a well-established technique and methods have been developed to purify a population of mesenchymal stem cells. Techniques have been developed to expand these progenitor cells over 1 billion-fold without losing their potency, and mesenchymal cells combined with a carrier have been demonstrated to have sufficient potency to heal critical-sized defects in both rat and canine models. [25] [26] [27] Although the results of using mesenchymal stem cells combined with a carrier to induce bone repair are quite promising, it still needs to be determined whether these cells have enough osteoinductive potential to heal a bone defect in a clinical situation. 40 The genetic manipulation of bone marrow cells to overexpress an osteoinductive protein could further enhance the bone repair response. Lieberman et al used an ex vivo gene transfer strategy to heal 8 mm femoral defects in a rat model (Figure 3 ). Bone Enhancement of bone repair AWA Baltzer and JR Lieberman marrow cells were harvested from rats, expanded in tissue culture, transduced with an Ad.BMP-2 vector and then implanted in a critical-sized femoral defect. The histomorphometric analysis revealed a more robust pattern of bone formation in femoral defects treated with the BMP-2-producing bone marrow cells than when compared with recombinant BMP-2 protein. It was hypothesized that the more robust bone formation associated with the BMP-producing bone marrow cells could be the result of the more continuous and physiological release of the release of BMP protein compared with the kinetics of BMP from the guanidine-extracted demineralized bone matrix used as a carrier in this experiment. 10 Genetically, engineered muscle-derived cells also have osteogenic potential. Lee et al demonstrated that muscle cells transduced with Ad.BMP-2 could heal critical-sized calvarial defects in SCID mice. The same group of investigators transduced muscle-derived stem cells with retroviruses containing the cDNAs for either VEGF or BMP-4, or both BMP-4 and VEGF. More bone was produced in calvarial defects that were treated with muscle-derived stem cells that had been transduced with retroviruses containing both BMP-4 and VEGF genes than when either BMP-4-or VEGF-transduced cells were implanted alone. The results of this study also suggest that the delivery of multiple genes may enhance bone repair. 28, 43 Recently, adipose-derived stem cells have been harvested from fat and these cells show potential as agents to be used in tissue engineering strategies. It has been demonstrated that human adipose tissues contain fibroblast-like cells that can behave in a similar manner to mesenchymal stem cells. When these cells are harvested from adipose tissue and grown in the appropriate media, they can differentiate into bone, cartilage, muscle or fat. 29 Human adipose-derived stem cells transduced with Ad.BMP-2 can successfully heal a critical-sized defect in nude rats. 30 These cells are easy to harvest and expand and the population of these cells in humans does not seem to decline with age.
Skin fibroblasts are attractive cellular delivery vehicles because they are easy to harvest and are readily available in all patients. BMP-7-transfected rats fibroblasts have been shown to heal calvarial defects in Lewis rats. 31 One potential problem when using fibroblasts to deliver osteoinductive signals is that fibrous tissue can actually inhibit bone formation and is the predominant tissue type in fracture nonunion sites.
It may be possible that other cytokines and growth factors have more osteoinductive activity than BMP-2 or -7. 39, 52 For example, Boden et al have recently reported that regional gene therapy using an adenovirus containing the cDNA for LIM mineralization protein-1 (LMP-1) can successfully induce spinal fusion in rodents and rabbits. The LMP-1 is a transcription factor that seems to induce the expression of several bone different BMPs, 32, 24 and it has been used successfully to enhance repair in an ex vivo gene therapy strategy. These investigators have been able to extract buffy coat cells from peripheral blood, transfect the cells after a short period of infection and fuse rabbit spines. The ability to use an ex vivo strategy during the same operation and without tissue culture expansion of cells is an attractive strategy.
Spine fusion
Autogenous bone graft has been the most commonly used agent to induce fusion of the spine. Although spine fusions are generally successful, pseudoarthrosis rates can range from 5 to 35% and there is morbidity associated with graft harvest. 33 The success of a spine fusion is influenced by a number of factors, including the overall mechanical stability of the spine, stability of fixation, the quality of bone and the surrounding soft tissue and the concurrent use of medications. 5 Recombinant BMP-2 in a collagen sponge has been used successfully to fuse the spine in humans, but there are concerns about the high doses of protein that are required. 51 In addition, at the present time recombinant BMP-2 is only approved for use in conjunction with a metallic cage via an anterior approach to the spine. Some surgeons do not want to use the anterior approach in males for routine spine fusions because of concerns about the development of retrograde ejaculation if there is damage to the parasympathetic nervous system.
In preclinical models, both bone marrow cells and buffy coat cells (bone marrow or blood) have been transduced with an adenovirus containing the cDNA for the transcription factor called LMP-1 and used successfully to fuse the intertransverse process of the spine in both rats and rabbits. The peripheral blood cells are attractive cellular delivery vehicles because they are easy to harvest. A potential disadvantage of using blood cells is that these cells are unlikely to have the same autocrine response to the secretion of osteoinductive problems as transduced stem cells. LMP-1 clearly has significant clinical potential and could be adapted to treat other bone repair problems in addition to fusion of the spine. Further analyses of LMP-1 are necessary because there could be side effects associated with the overexpression of this transcription factor. No overexpression or transgenic animal models for LMP-1 have been reported to date and further investigations of the potential side effects of LMP-1 are necessary. 5 Wang et al 33, 53 used Ad.BMP-2 to induce intertransverse lumbar spinal fusions successfully in rats. The same strategy using BMP-2-producing bone marrow cells to heal critical-sized femoral defects was employed to induce fusion of the spine. 10 Bone marrow cells were harvested from the femurs of rats, expanded in tissue culture and then transduced with Ad.BMP-2. The transduced cells were then implanted into the fusion sites and guanidine-extracted demineralized bone matrix or collagen sponges were used as carriers. All 15 spines treated in this manner fused. In contrast, bone marrow cells that were not transduced did not induce fusion of the spine (Figure 4 ). These same investigators have also transduced human bone marrow cells with an adenovirus containing the cDNA for BMP-2 and were able to induce fusion of the spines in nude rats. 34 These studies with human cells demonstrate proof of the concept that human cells can be genetically manipulated to overexpress osteoinductive proteins and enhance bone repair.
Recently, BMP-9 has been used to induce fusion of the spine in rats using a direct injection technique. 35, 50 In the future, the ability to deliver growth factors via gene therapy may enhance the development of less invasive operative techniques such as laparoscopic spine fusion. 
Conclusion
The preclinical data presented in this review clearly demonstrate that regional gene therapy can be adapted for use in humans. Human cells have now been used to heal critical-sized defects and induce spinal fusion in animal models. 30, 34 However, gene therapy should be viewed as only one aspect of a more comprehensive tissue engineering approach to treating bone repair problems in patients. Autologous bone graft, cell-based therapy and recombinant proteins will be used to treat a variety of bone loss proteins. Gene therapy will not be necessary for all patients. In addition, as investigators develop gene therapy strategies to treat musculoskeletal problems, we must remember that for the most part these new molecular therapies will be used to improve patient's quality of life and not to cure life-threatening illness. Therefore, patient safety must be our number one priority as these new techniques are taken from the bench to the bedside.
